Loper Bright and Jarkesy: What Do They Mean for the Health Care Industry?

The health care industry is still parsing the effects of the Supreme Court’s recent decisions in Loper Bright Enterprises v. Raimondo, which ends Chevron deference, and SEC v. Jarkesy, which entitles defendants to a jury trial when the government seeks civil penalties. Chip Hutzler, Partner, HMS Valuation Partners, speaks with Greg Demske, Partner, Goodwin Procter LLP, and Jonathan Porter, Partner, Husch Blackwell LLP, about how these decisions will impact the health care industry. They discuss which health care regulations may come under closer scrutiny after Loper Bright and the kinds of health care civil penalties that may be affected under Jarkesy. Jonathan recently co-authored an article for Health Law Weekly about this topic. From AHLA’s Fraud and Abuse Practice Group. Sponsored by HMS Valuation Partners.Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

There are no comments yet.

Please log in to write the first comment.